Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

TURP Inpatient With Underactive Bladder With BOO

NCT06944743 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-04-01
Last updated
2025-04-25

Condition(s) studied

TURP SyndromeRetention, UrinaryProstate Disease

Investigational drug(s) / intervention(s)

Transurtheral Resection of prostate ( TURP)

Transurtheral Resection of prostate ( TURP): TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones). The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria.

Study summary

The study is for aproved that Transurtheral Resection of prostate is good for patient with underactive bladder or not.

Eligibility

Sex
MALE
Min age
40 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Male patients diagnosed with BOO and UAB * Age ≥ 40 years. Exclusion Criteria: * Patient insulin dependent diabetes * Patient with history of cerbrovascular stroke or hemarrage. * History of prior prostate surgery. * Urethral pathology or surgery. * Patient with prostate or bladder cancer. * Spinal and pelvic trauma or surgery.

Primary outcome measure(s)

  • Change in international prostate symptome score (IPSS) score. — 3 month .
    Outcome measure Detrusar pressure at maximum flow (Pdet-Qmax unit:CmH2O)

Trial sites (1)

FacilityCityRegionStatus
Emad Abdellah Ali Mostafa Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06944743 on ClinicalTrials.gov ↗ ← All trials in Egypt